Sarepta provided guidance for total net product revenue in 2026 of $1.2 billion to $1.4 billion for approved therapies. Ingram specified, "Without our educational efforts, we would expect to track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results